Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)

NCT00684970 is registered in ClinicalTrials.gov with Tiltan Pharma Ltd. as lead sponsor.

NCT NCT00684970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00684970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
Lead sponsor
Tiltan Pharma Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2009
Completion date
Not reported
Enrollment
100 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer (crpc)